~~<i id='FCBB57069B'><strike id='FCBB57069B'><tt id='FCBB57069B'><pre id='FCBB57069B'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：Wikipedia 2025-09-30 23:27:44 Page View：775

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Changes to biosimilar regulatory framework must prioritize patients
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

CDC's new outbreak response network to include Northeastern

MarkSchiefelbein/APNortheasternUniversityhasbeenselectedforaleadingroleinanewnationalnetworkformedto

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

Why you get paid to donate plasma but not blood

Payingblooddonorsmightleadpeopletoconcealriskybehaviors.JoernPollex/GettyImagesDonatingplasmaanddona